

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CLSA Premium Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6877)

VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS AND THE STRATEGIC COOPERATION AGREEMENT

This announcement is made by CLSA Premium Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company noted unusual fluctuations in the price and trading volume of the Company’s shares on 18 November 2022. Having made all enquiries with respect to the Company as are reasonable in the circumstances, the Board confirms that it is not aware of any reasons for such price and volume movements or of any information which must be announced to avoid a false market in the Company’s securities, or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

THE STRATEGIC COOPERATION AGREEMENT

The Board is pleased to announce that on 18 November 2022 (after trading hours), the Company and Beijing Tong Ren Tang (Cayman) Limited (“**TRT International**”) entered into a strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) for the development of healthcare business (including Chinese medicine), pursuant to which the Company and TRT International agreed to establish a strategic cooperation relationship.

Pursuant to the Strategic Cooperation Agreement, the parties agreed that the cooperation between the Company and TRT International will include, among other things, the following:-

- (i) **Technical assistance** - TRT International to provide assistance to the Company in healthcare product specialty, procurement channel, product development and Chinese medicine application.
- (ii) **Training** - TRT International to provide training to the Company on the healthcare business and Chinese medicine.
- (iii) **Secondment** - TRT International to second staff with healthcare experience to the Company.
- (iv) **Network-building** - the Company and TRT International shall provide introduction of their own network and personnel in the healthcare business (including Chinese medicine) reciprocally in order to enhance, among others, network building.
- (v) **Further Collaboration** - the Company and TRT International may respectively consider a possible or reciprocal funding or support to each other, subject to the development of healthcare business collaboration and market condition.
- (vi) **License in selling Chinese medicines** - given the Group has the wholesaler license in proprietary Chinese medicines, it should provide reasonable assistance and channel to TRT International to distribute Chinese medicines in the Greater China region.

REASONS FOR THE ENTERING INTO OF THE STRATEGIC COOPERATION AGREEMENT

The Group understands that TRT International is an enterprise combined innovative health and ecological via internet. Through the Internet Plus model, it efficiently integrates global health and medical resources, and combines mobile internet technology, health cloud computing, artificial intelligence technology, etc. to serve and to provide high-quality professional health products and health services to global consumers. The business of TRT International group includes the traditional Chinese medicine internet hospital platform and a cross-border e-commerce platform.

The Board believes that by entering into the Strategic Cooperation Agreement would enable the Group to leverage on the expertise of TRT International group for expanding the modular management and expansion of healthcare products businesses (including Chinese medicine) and would play a positive role in diversifying the revenue stream of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares and/or securities of the Company.

By Order of the Board
CLSA Premium Limited
Yuan Feng
Executive Director

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yuan Feng (*Deputy Chief Executive Officer*)

Mr. Chung Cheuk Fan Marco

Non-executive Directors

Mr. Li Jiong (*Chairman*)

Mr. Xu Jianqiang

Independent non-executive Directors

Mr. Wu Jianfeng

Mr. Christopher Wesley Satterfield

Ms. Hu Zhaoxia